Biological therapy for the prevention and treatment of postoperative endoscopic recurrence in Crohn's disease: time for acceptance?

Detalhes bibliográficos
Autor(a) principal: Kotze, Paulo Gustavo
Data de Publicação: 2013
Outros Autores: Hossne, Rogério Saad [UNESP]
Tipo de documento: Artigo
Idioma: eng
Título da fonte: Repositório Institucional da UNESP
Texto Completo: http://dx.doi.org/10.5217/ir.2013.11.4.256
http://hdl.handle.net/11449/136813
Resumo: In most patients, postoperative endoscopic recurrence (PER) occurs 1 year after abdominal resection for Crohn’s disease (CD). Preventing PER is essential for disease control, as most patients develop further clinical and surgical recurrences. Conventional therapy with nitroimidazoles, aminosalicylates, and immunomodulators have limited efficacy for preventing PER. Initial trials with biological therapy (infliximab and adalimumab) showed promising results in preventing PER, and the efficacy of these drugs seems higher than that with conventional therapy. The aim of this review is to outline the results of studies that used infliximab or adalimumab for preventing and treating PER in CD patients. Data with both agents are available, and a few, small prospective trials have shown the efficacy of these drugs in patients with a high risk for recurrence. We believe that, in 2013, biological agents will be better accepted for the prevention PER in CD patients, in addition to the already existing data. Larger trials are still underway, and their results will certainly determine the role of these agents in PER, which develops after bowel resection for CD.
id UNSP_dba450949f2d6f541f619d1d9a64783b
oai_identifier_str oai:repositorio.unesp.br:11449/136813
network_acronym_str UNSP
network_name_str Repositório Institucional da UNESP
repository_id_str 2946
spelling Biological therapy for the prevention and treatment of postoperative endoscopic recurrence in Crohn's disease: time for acceptance?Tumor necrosis factor alphaCrohn’s diseaseRecurrenceIn most patients, postoperative endoscopic recurrence (PER) occurs 1 year after abdominal resection for Crohn’s disease (CD). Preventing PER is essential for disease control, as most patients develop further clinical and surgical recurrences. Conventional therapy with nitroimidazoles, aminosalicylates, and immunomodulators have limited efficacy for preventing PER. Initial trials with biological therapy (infliximab and adalimumab) showed promising results in preventing PER, and the efficacy of these drugs seems higher than that with conventional therapy. The aim of this review is to outline the results of studies that used infliximab or adalimumab for preventing and treating PER in CD patients. Data with both agents are available, and a few, small prospective trials have shown the efficacy of these drugs in patients with a high risk for recurrence. We believe that, in 2013, biological agents will be better accepted for the prevention PER in CD patients, in addition to the already existing data. Larger trials are still underway, and their results will certainly determine the role of these agents in PER, which develops after bowel resection for CD.Pontifícia Universidade Católica do Paraná (PUC-PR), Departamento de Cirurgia, Curitiba, PR, BrasilUniversidade Estadual Paulista Júlio de Mesquita Filho (UNESP), Faculdade de Medicina de Botucatu (FMB), Departamento de Cirurgia e Ortopedia, Botucatu, SP, BrasilUniversidade Estadual Paulista Júlio de Mesquita Filho (UNESP), Faculdade de Medicina de Botucatu (FMB), Departamento de Cirurgia e Ortopedia, Botucatu, SP, BrasilPontifícia Universidade Católica do Paraná (PUC-PR)Universidade Estadual Paulista (Unesp)Kotze, Paulo GustavoHossne, Rogério Saad [UNESP]2016-04-01T18:42:42Z2016-04-01T18:42:42Z2013info:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article256-260application/pdfhttp://dx.doi.org/10.5217/ir.2013.11.4.256Intestinal Research, v. 11, n. 4, p. 256-260, 2013.1598-9100http://hdl.handle.net/11449/13681310.5217/ir.2013.11.4.256ISSN1598-9100-2013-11-04-256-260.pdf952634515659047795263451565904779526345156590477Currículo Lattesreponame:Repositório Institucional da UNESPinstname:Universidade Estadual Paulista (UNESP)instacron:UNESPengIntestinal Research1,074info:eu-repo/semantics/openAccess2024-08-14T14:19:17Zoai:repositorio.unesp.br:11449/136813Repositório InstitucionalPUBhttp://repositorio.unesp.br/oai/requestopendoar:29462024-08-14T14:19:17Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)false
dc.title.none.fl_str_mv Biological therapy for the prevention and treatment of postoperative endoscopic recurrence in Crohn's disease: time for acceptance?
title Biological therapy for the prevention and treatment of postoperative endoscopic recurrence in Crohn's disease: time for acceptance?
spellingShingle Biological therapy for the prevention and treatment of postoperative endoscopic recurrence in Crohn's disease: time for acceptance?
Kotze, Paulo Gustavo
Tumor necrosis factor alpha
Crohn’s disease
Recurrence
title_short Biological therapy for the prevention and treatment of postoperative endoscopic recurrence in Crohn's disease: time for acceptance?
title_full Biological therapy for the prevention and treatment of postoperative endoscopic recurrence in Crohn's disease: time for acceptance?
title_fullStr Biological therapy for the prevention and treatment of postoperative endoscopic recurrence in Crohn's disease: time for acceptance?
title_full_unstemmed Biological therapy for the prevention and treatment of postoperative endoscopic recurrence in Crohn's disease: time for acceptance?
title_sort Biological therapy for the prevention and treatment of postoperative endoscopic recurrence in Crohn's disease: time for acceptance?
author Kotze, Paulo Gustavo
author_facet Kotze, Paulo Gustavo
Hossne, Rogério Saad [UNESP]
author_role author
author2 Hossne, Rogério Saad [UNESP]
author2_role author
dc.contributor.none.fl_str_mv Pontifícia Universidade Católica do Paraná (PUC-PR)
Universidade Estadual Paulista (Unesp)
dc.contributor.author.fl_str_mv Kotze, Paulo Gustavo
Hossne, Rogério Saad [UNESP]
dc.subject.por.fl_str_mv Tumor necrosis factor alpha
Crohn’s disease
Recurrence
topic Tumor necrosis factor alpha
Crohn’s disease
Recurrence
description In most patients, postoperative endoscopic recurrence (PER) occurs 1 year after abdominal resection for Crohn’s disease (CD). Preventing PER is essential for disease control, as most patients develop further clinical and surgical recurrences. Conventional therapy with nitroimidazoles, aminosalicylates, and immunomodulators have limited efficacy for preventing PER. Initial trials with biological therapy (infliximab and adalimumab) showed promising results in preventing PER, and the efficacy of these drugs seems higher than that with conventional therapy. The aim of this review is to outline the results of studies that used infliximab or adalimumab for preventing and treating PER in CD patients. Data with both agents are available, and a few, small prospective trials have shown the efficacy of these drugs in patients with a high risk for recurrence. We believe that, in 2013, biological agents will be better accepted for the prevention PER in CD patients, in addition to the already existing data. Larger trials are still underway, and their results will certainly determine the role of these agents in PER, which develops after bowel resection for CD.
publishDate 2013
dc.date.none.fl_str_mv 2013
2016-04-01T18:42:42Z
2016-04-01T18:42:42Z
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://dx.doi.org/10.5217/ir.2013.11.4.256
Intestinal Research, v. 11, n. 4, p. 256-260, 2013.
1598-9100
http://hdl.handle.net/11449/136813
10.5217/ir.2013.11.4.256
ISSN1598-9100-2013-11-04-256-260.pdf
9526345156590477
9526345156590477
9526345156590477
url http://dx.doi.org/10.5217/ir.2013.11.4.256
http://hdl.handle.net/11449/136813
identifier_str_mv Intestinal Research, v. 11, n. 4, p. 256-260, 2013.
1598-9100
10.5217/ir.2013.11.4.256
ISSN1598-9100-2013-11-04-256-260.pdf
9526345156590477
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv Intestinal Research
1,074
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv 256-260
application/pdf
dc.source.none.fl_str_mv Currículo Lattes
reponame:Repositório Institucional da UNESP
instname:Universidade Estadual Paulista (UNESP)
instacron:UNESP
instname_str Universidade Estadual Paulista (UNESP)
instacron_str UNESP
institution UNESP
reponame_str Repositório Institucional da UNESP
collection Repositório Institucional da UNESP
repository.name.fl_str_mv Repositório Institucional da UNESP - Universidade Estadual Paulista (UNESP)
repository.mail.fl_str_mv
_version_ 1808128168788230144